Table 3. Univariate and multivariate analyses of independent risk factors of the total plasm cfDNA in HBV-related HCC patients (n=48).
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (years) | 1.02 (0.97–1.07) | 0.536 | – | – | |
| Albumin (g/L) | 0.84 (0.73–0.97) | 0.020 | 1.03 (0.84–1.27) | 0.780 | |
| PLT (109/L) | 0.99 (0.98–1.004) | 0.204 | – | – | |
| Total bilirubin (μmol/L) | 1.02 (0.92–1.13) | 0.690 | – | – | |
| Direct bilirubin (μmol/L) | 1.05 (0.85–1.31) | 0.630 | – | – | |
| ALT (U/L) | 1.004 (0.99–1.02) | 0.608 | – | – | |
| AST (U/L) | 1.02 (0.99–1.04) | 0.148 | – | – | |
| PT (s) | 1.77 (0.93–3.36) | 0.081 | – | – | |
| Tumor diameter (cm) | 1.38 (1.13–1.68) | 0.002 | 1.48 (1.06–2.09) | 0.023 | |
| MELD score | 1.93 (0.44–8.43) | 0.381 | – | – | |
| HBV-DNA (≥106 vs. <106 IU/mL) | 2.68 (0.34–21.12) | 0.353 | – | – | |
| Tumor capsular (absence vs. presence) | 4.0 (0.45–35.49) | 0.213 | – | – | |
| AFP (>20 vs. ≤20 ng/mL) | 2.57 (0.60–10.92) | 0.202 | – | – | |
| Edmondson grade (III–IV vs. I–II) | 2.89 (0.75–11.11) | 0.122 | – | – | |
| Satellite nodules (presence vs. absence) | 1.03 (0.18–6.09) | 0.970 | – | – | |
| Cirrhosis (presence vs. absence) | 1.11 (0.28–4.45) | 0.882 | – | – | |
| Tumor number (single vs. multiple) | 0.17 (0.04–0.71) | 0.015 | 0.35 (0.04–3.57) | 0.377 | |
| Vascular invasion (absence vs. presence) | 0.03 (0.003–0.29) | 0.002 | 0.04 (0.002–0.82) | 0.036 | |
| CTP class (A vs. B) | 0.08 (0.008–0.76) | 0.028 | 0.03 (0.001–0.75) | 0.033 | |
| TNM stage (I/II vs. III) | 0.07 (0.015–0.36) | 0.001 | 0.31 (0.03–3.28) | 0.329 | |
PLT, platelet; ALT, Alanine transaminase; AST, glutamic oxaloacetic transaminase; PT, prothrombin time; MELD, Model for end-stage liver disease; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh; TNM stage, Tumor, Lymph Node and Metastasis stage.